AstraZeneca and MSD have presented data at ASCO showing improvement in radiologic progression-free survival (rPFS) in prostate cancer patients taking a combination of Lynparza and abiraterone.
Study 08 – a randomised, double-blinded, multi-centre Phase II trial – compared Lynparza (olaparib) in combination with abiraterone to abiraterone alone in patients with previously-treated metastatic castration-resistant prostate cancer, (mCRPC), regardless of homologous recombination repair (HRR) mutation status.
The results, published online today in the Lancet Oncology, showed that median rPFS was 13.8 months in the combination arm compared to 8.2 months with abiraterone alone.
Median overall survival was 22.7 months with combination treatment versus 20.9 months with abiraterone alone.
“There is a significant unmet medical need for patients with metastatic castration-resistant prostate cancer as they are a high-risk group with limited treatment options. Lynparza is the first PARP inhibitor to demonstrate activity in combination with standard-of-care treatment in prostate cancer,” noted Roy Baynes, senior vice president and head of Global Clinical Development, chief medical officer, MSD Research Laboratories.
